-selectivity in the radical addition. These key mechanisms have been theoretically validated through DFT calculations. Notably, the protocol is distinguished by broad functional group compatibility, scalability, high energy efficiency, and mild conditions, demonstrating practicality in the late-stage modification of biorelevant compounds and the synthesis of pharmaceutical intermediates, including IDO inhibitors, which represent a clinically relevant class of small molecules in cancer immunotherapy.
Wang et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: